Publications

5538 Results

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

Authors
DS Alberts;S Green;EV Hannigan;R O'Toole;D Stock-Novack;P Anderson;EA Surwit;VK Malvlya;WA Nahhas;CJ Jolles
Journal / Conference
Classic Papers and Current Comments 3(1):145-157
Year
1998
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8412

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial.

Authors
H Koops;M Vaglini;S Suciu;BBR Kroon;JF Thompson;J Gohl;AMM Eggermont;F Di Filippo;ET Krementz;D Ruiter;FJ Lejeune
Journal / Conference
Journal of Clinical Oncology 16(9):2906-2912
Year
1998
Research Committee(s)
Melanoma
Study Number(s)
SWOG-8593 (INT-0065)

New REAL clinical entities.

Authors
RI Fisher;TP Miller;TM Grogan
Journal / Conference
Cancer Journal from Scientific American 4(Suppl.2):S5-S12
Year
1998
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7204/7205, SWOG-7426/7427, SWOG-7713/14

Inadequate documentation and resection for gastric cancer in the United States: A preliminary report.

Authors
NC Estes;JS Macdonald;K Touijer;J Benedetti;J Jacobson
Journal / Conference
The American Surgeon 64(7):680-685
Year
1998
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195)

Design and analysis for survival data under order restrictions with a modified logrank test.

Authors
PY Liu;WY Tsai;M Wolf
Journal / Conference
Statistics in Medicine 17:1469-1479
Year
1998
Research Committee(s)
Multiple sites

EBV DNA quantitation in serum is highly correlated with the development and regression of post-transplant lymphoproliferative disorder (PTLD) in solid organ tranplant recipients.

Authors
LJ Swinnen;ML Gulley;E Hamilton;SA Schichman
Journal / Conference
Blood 92(10)(Suppl.1):314a-315a(#1291)
Year
1998
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-9239

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An intergroup study.

Authors
JH Fetting;R Gray;DL Fairclough;TJ Smith;KA Margolin;ML Citron;M Grove-Conrad;D Cella;K Pandya;N Robert;IC Henderson;CK Osborne;MD Abeloff
Journal / Conference
Journal of Clinical Oncology 16(7):2382-2391
Year
1998
Research Committee(s)
Breast
Study Number(s)
SWOG-8931 (INT-0108) (EST-3189)

Benefit of cycloporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study.

Authors
AF List;KJ Kopecky;CL Willman;C Spier;R Dorr;L Flaherty;H Hynes;F Appelbaum
Journal / Conference
Blood 92(10)(Suppl.1):312a(#1281)
Year
1998
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9126

Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients.

Authors
J Berenson;J Crowley;B Barlogie;S Salmon
Journal / Conference
Blood 92(10(Suppl.1):318a(#1305)
Year
1998
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9210

Karyotypic analysis predicts outcome of pre-and post- remission therapy in adult acute myeloid leukemia (AML): A SWOG/ECOG intergroup study.

Authors
ML Slovak;KJ Kopecky;PA Cassileth;DH Harrington;K Theil;A Mohamed;A Chung;E Paietta;C Willman;DR Head;SJ Forman;FR Appelbaum
Journal / Conference
Blood 92(10)(Suppl.1):678a(#2795)
Year
1998
Research Committee(s)
Leukemia
Study Number(s)
SWOG-9034 (EST-3489) (CALGB-9120)